Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alprostadil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 known ✓ | P43116 | 4/20 | 1.00 |
| ▸ | PTGER1 known ✓ | P34995 | 1/20 | 0.73 |
| ▸ | PTGIR | P43119 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | PTGER4 | P35408 | 3/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprostadil SCHEMBL5303767 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL12987687 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL11695818 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL11864105 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23353047 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL7742103 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23353103 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL23352620 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| SCHEMBL23352905 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 | |
| Alprostadil SCHEMBL22425786 | 1.00 | PTGIR (1.00) | PTGIRPTGER2TSHRPTGER4NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15158 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144751-A1 | LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOF | PHARMOSA BIOPHARM INC. (TW) | 2026-05-28 | — | — | US | claimed |
| CN-122075386-A | Intravesical drug delivery system and preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105727-A1 | FORMULATION FOR TREATING SPINAL CORD DISEASE IN DOG AND METHOD FOR TREATING SPINAL CORD DISEASE IN DOG | 東レ株式会社 | 2026-05-21 | — | — | WO | claimed |
| EP-3729084-B1 | IMMUNE CELL ORGANOID CO-CULTURES | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-05-20 | — | — | EP | claimed |
| CN-121622700-B | Use of prostaglandin PGE1 or PGE2 for the preparation of a product promoting proliferation of depleted precursor T cells | 暨南大学 | 2026-05-19 | — | — | CN | claimed |
| CN-122031142-A | Targeted drug delivery device for improving coronary microcirculation disturbance | 雄安宣武医院 | 2026-05-15 | — | — | CN | claimed |
| WO-2026099311-A2 | MICROBIAL CELL FACTORIES PRODUCING PROSTAGLANDINS | RIVER STONE BIOTECH APS (DK) | 2026-05-15 | — | — | WO | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| WO-1997029735-A1 | DERMAL PENETRATION ENHANCERS AND DRUG DELIVERY SYSTEMS INVOLVING SAME | MONASH UNIVERSITY (AU) | 1997-08-21 | — | — | WO | claimed |
| WO-1997017078-A1 | USE OF POLYETHYLENE GLYCOL FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE MUCOUS MEMBRANES | BANNERT CHRISTIAN (DE) | 1997-05-15 | — | — | WO | claimed |
| US-5474535-A | Dosage and inserter for treatment of erectile dysfunction | VIVUS, INC. (US) | 1995-12-12 | — | — | US | claimed |
| US-5472954-A | Combining cyclodextrin with polymer before adding active material | CYCLOPS H.F. (IS) | 1995-12-05 | — | — | US | claimed |
| US-5324718-A | Complexing with natural and synthetic polymers; high speed drug release | CYCLOPS H.F. (IS) | 1994-06-28 | — | — | US | claimed |
| EP-0579435-A1 | Cyclodextrin complexation | CYCLOPS h.f. (IS) | 1994-01-19 | — | — | EP | claimed |
| EP-0459377-A2 | Use of E1 prostaglandin to cure male erectile inpotence | Reale, Alberto (IT) | 1991-12-04 | — | — | EP | claimed |
| US-5024998-A | Administering in aqueous solution with cyclodextrin derivative | UNIVERSITY OF FLORIDA (US) | 1991-06-18 | — | — | US | claimed |
| US-4983586-A | Decreasing precipitation at injection site or in lungs or other organs by combining with hydroxypropyl-beta-cyclodextrin | UNIVERSITY OF FLORIDA (US) | 1991-01-08 | — | — | US | claimed |
| EP-0335545-A2 | Pharmaceutical formulations for parenteral use | UNIVERSITY OF FLORIDA (US) | 1989-10-04 | — | — | EP | claimed |